Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan-Apr;9(1):16-23.
doi: 10.4103/sjmms.sjmms_731_20. Epub 2020 Dec 26.

Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia

Nawal AlShehry  1 , Syed Ziauddin A Zaidi  1 , Ahmed AlAskar  2 , Abdurahman Al Odayani  3 , Jawaher Mubarak Alotaibi  4 , Ahmed AlSagheir  5 , Ayman Al-Eyadhy  6 , Saud Balelah  7 , Abdul Salam  8 , Abdul Rehman Zia Zaidi  9   10   11 , Diea Alawami  12 , Mohammed S Alshahrani  13 , Nour AlMozain  14   15 , Yem M Abulhamayel  16 , Reem Al Qunfoidi  17 , Mona Alfaraj  18 , Nahid Qushmaq  19 , Rehab Alansari  20 , Afra Dayel  21 , Ghada Elgohary  15   22 , Ahmed Al Bahrani  23 , Arwa A Nabhan Abdelhameed  24 , Hazza Abdullah AlZahrani  25 , Hanan Alturkistani  26 , Nada AlShehry  27 , Mohammed Abdulhameed Albalawi  28 , Ibrahim Elalfy  29 , Hind Alhumaidan  30 , Hani Al-Hashmi  12 ; KSA COVID-19 Convalescent Plasma Study Group
Affiliations

Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia

Nawal AlShehry et al. Saudi J Med Med Sci. 2021 Jan-Apr.

Erratum in

Abstract

Objective: To present the interim findings from a national study investigating the safety and efficacy of convalescent plasma (CP) containing detectable IgG antibodies as a treatment strategy for severe coronavirus disease 2019 (COVID-19).

Trial design and participants: An open label, two-arm, phase-II clinical trial conducted across 22 hospitals from Saudi Arabia. The intervention group included 40 adults (aged ≥18 years) with confirmed severe COVID-19 and the control group included 124 patients matched using propensity score for age, gender, intubation status, and history of diabetes and/or hypertension. Intervention group included those (a) with severe symptoms (dyspnea; respiratory rate, ≥30/min; SpO2, ≤93%, PaO2/FiO2 ratio, <300; and/or lung infiltrates >50% within 24-48 h), (b) requiring intensive care unit (ICU) care or (c) experiencing life-threatening conditions. The control group included confirmed severe COVID-19 patients of similar characteristics who did not consent for CP infusion or were not able to receive CP due to its nonavailability.

Interventions: The intervention group participants were infused 300 ml (200-400 ml/treatment dose) CP at least once, and if required, daily for up to 5 sessions, along with receiving the best standard of care. The control group only received the best standard of care.

Outcomes: The primary endpoints were safety and ICU length of stay (LOS). The secondary endpoints included 30-day mortality, days on mechanical ventilation and days to clinical recovery.

Results: CP transfusion did not result in any adverse effects. There was no difference in the ICU LOS (median 8 days in both groups). The mortality risk was lower in the CP group: 13% absolute risk reduction (P = 0.147), hazard ratio (95% confidence interval): 0.554 (0.299-1.027; P = 0.061) by log-rank test. There was no significant difference in the days on mechanical ventilation and days to clinical recovery.

Conclusion: CP containing detectable antibodies is a safe strategy and may result in a decrease in mortality in patients with severe COVID-19. The results of the completed trial with a larger study sample would provide more clarity if this difference in mortality is significant.

Trial registration: ClinicalTrials.gov Identifier: NCT04347681; Saudi Clinical Trials Registry No.: 20041102.

Keywords: Antibodies; COVID-19; SARS-CoV-2; Saudi Arabia; convalescent plasma.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Logistic cycle of convalescent plasma procurement from donor, processing and transfusion to COVID-19 patient
Figure 2
Figure 2
Survival probability between CP group and matched control patients
Figure 3
Figure 3
Sub-group survival probability of the CP group
See this image and copyright information in PMC

References

    1. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757–65. - PMC - PubMed
    1. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92:479–90. - PMC - PubMed
    1. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158:e9–13. - PMC - PubMed
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398–400. - PMC - PubMed
    1. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for ebola virus disease in Guinea. New England J Med. 2016;374:33–42. - PMC - PubMed

Associated data